Regulus Therapeutics (RGLS) Competitors $1.94 -0.01 (-0.51%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RGLS vs. ZBIO, RIGL, VSTM, VNDA, EBS, XOMA, IRWD, CDXS, SGMO, and LXRXShould you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Codexis (CDXS), Sangamo Therapeutics (SGMO), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry. Regulus Therapeutics vs. Zenas Biopharma Rigel Pharmaceuticals Verastem Vanda Pharmaceuticals Emergent BioSolutions XOMA Ironwood Pharmaceuticals Codexis Sangamo Therapeutics Lexicon Pharmaceuticals Regulus Therapeutics (NASDAQ:RGLS) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations. Do insiders and institutionals hold more shares of RGLS or ZBIO? 92.4% of Regulus Therapeutics shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate RGLS or ZBIO? Regulus Therapeutics currently has a consensus price target of $12.75, suggesting a potential upside of 557.22%. Zenas Biopharma has a consensus price target of $40.00, suggesting a potential upside of 380.19%. Given Regulus Therapeutics' higher possible upside, equities analysts clearly believe Regulus Therapeutics is more favorable than Zenas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer RGLS or ZBIO? Regulus Therapeutics received 492 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 63.99% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes49463.99% Underperform Votes27836.01% Zenas BiopharmaOutperform Votes2100.00% Underperform VotesNo Votes Does the media favor RGLS or ZBIO? In the previous week, Zenas Biopharma had 9 more articles in the media than Regulus Therapeutics. MarketBeat recorded 12 mentions for Zenas Biopharma and 3 mentions for Regulus Therapeutics. Regulus Therapeutics' average media sentiment score of 0.18 beat Zenas Biopharma's score of 0.05 indicating that Regulus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regulus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is RGLS or ZBIO more profitable? Zenas Biopharma's return on equity of 0.00% beat Regulus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -53.07% -48.58% Zenas Biopharma N/A N/A N/A Which has higher earnings and valuation, RGLS or ZBIO? Regulus Therapeutics has higher earnings, but lower revenue than Zenas Biopharma. Zenas Biopharma is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$0.87-2.23Zenas Biopharma$5M69.64-$148.39M-$3.55-2.35 SummaryRegulus Therapeutics beats Zenas Biopharma on 9 of the 14 factors compared between the two stocks. Remove Ads Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGLS vs. The Competition Export to ExcelMetricRegulus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.51M$6.26B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.816.6921.6517.68Price / SalesN/A222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book1.855.776.373.94Net Income-$30.04M$142.01M$3.20B$247.45M7 Day Performance13.45%2.88%1.79%0.48%1 Month Performance31.08%-13.93%-9.41%-7.08%1 Year Performance-24.22%-12.36%9.61%-0.35% Regulus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGLSRegulus Therapeutics2.424 of 5 stars$1.94-0.5%$12.75+557.2%-29.9%$128.51MN/A-1.8130Short Interest ↑Gap DownZBIOZenas BiopharmaN/A$7.75+0.5%$40.00+416.1%N/A$323.94M$5M-2.18N/ANews CoverageGap DownHigh Trading VolumeRIGLRigel Pharmaceuticals2.7678 of 5 stars$17.04-1.2%$36.80+116.0%+48.2%$304.39M$179.28M121.72160News CoveragePositive NewsVSTMVerastem3.0735 of 5 stars$5.10-1.2%$13.88+172.1%-56.5%$262.58M$10M-1.6050VNDAVanda Pharmaceuticals4.1686 of 5 stars$4.19+1.2%$16.50+293.8%+7.6%$244.34M$198.77M-13.09290News CoveragePositive NewsEBSEmergent BioSolutions4.3126 of 5 stars$4.43-1.9%$14.33+223.3%+134.1%$240.88M$1.01B-1.082,420Positive NewsXOMAXOMA4.3661 of 5 stars$19.23-1.1%$72.00+274.4%-14.5%$230.36M$10.22M-5.5310Gap UpIRWDIronwood Pharmaceuticals4.5629 of 5 stars$1.27-5.2%$8.60+577.2%-90.7%$203.24M$351.41M-42.33220Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownCDXSCodexis3.1454 of 5 stars$2.06-3.3%$8.33+304.5%-16.4%$170.64M$59.35M-2.37250Gap DownSGMOSangamo Therapeutics2.2007 of 5 stars$0.71+7.7%$5.17+630.9%+33.0%$158.85M$57.80M-0.94480Gap DownHigh Trading VolumeLXRXLexicon Pharmaceuticals2.8166 of 5 stars$0.52+23.5%$3.67+608.7%-72.6%$127.40M$31.08M-0.69140Analyst ForecastHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Zenas Biopharma Alternatives Rigel Pharmaceuticals Alternatives Verastem Alternatives Vanda Pharmaceuticals Alternatives Emergent BioSolutions Alternatives XOMA Alternatives Ironwood Pharmaceuticals Alternatives Codexis Alternatives Sangamo Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGLS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGLS Stock Free RGLS Stock Alerts